Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies
出版年份 2022 全文链接
标题
Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies
作者
关键词
-
出版物
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
Volume -, Issue -, Pages jnnp-2022-330175
出版商
BMJ
发表日期
2022-12-16
DOI
10.1136/jnnp-2022-330175
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant
- (2022) Yu Gao et al. NATURE MEDICINE
- Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine
- (2022) Yihao Liu et al. Cell Discovery
- Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine–induced antibody and T cell immunity and function
- (2022) Joseph J. Sabatino et al. JCI Insight
- Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod
- (2022) Anat Achiron et al. JOURNAL OF NEUROLOGY
- COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose
- (2022) Sapir Dreyer-Alster et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Establishment and recall of SARS-CoV-2 spike epitope-specific CD4+ T cell memory
- (2022) Kathleen M. Wragg et al. NATURE IMMUNOLOGY
- Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine
- (2022) Chiara Agrati et al. Scientific Reports
- Omicron-Specific Cytotoxic T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With Multiple Sclerosis Treated With Ocrelizumab
- (2022) Natacha Madelon et al. JAMA Neurology
- Longitudinal humoral response in MS patients treated with Cladribine tablets after receiving the second and third doses of SARS-CoV-2 mRNA vaccine
- (2022) Livnat Brill et al. Multiple Sclerosis and Related Disorders
- Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients
- (2022) Hamza Mahmood Bajwa et al. Multiple Sclerosis and Related Disorders
- Humoral response after the booster dose of anti-SARS-CoV-2 vaccine in multiple sclerosis patients treated with high-efficacy therapies
- (2022) Alessandro Maglione et al. Multiple Sclerosis and Related Disorders
- Humoral and cellular immunity in convalescent and vaccinated COVID-19 people with multiple sclerosis: Effects of disease modifying therapies
- (2022) Mario Habek et al. Multiple Sclerosis and Related Disorders
- Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis
- (2022) Chiara Farroni et al. Frontiers in Immunology
- Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple Sclerosis
- (2022) Linda Petrone et al. Frontiers in Neurology
- Effectiveness of mRNA Vaccination in Preventing COVID-19–Associated Invasive Mechanical Ventilation and Death — United States, March 2021–January 2022
- (2022) Mark W. Tenforde et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod
- (2022) Virginia Palomares Cabeza et al. Neurology-Neuroimmunology & Neuroinflammation
- Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune mediated inflammatory diseases
- (2022) Roya M. Dayam et al. JCI Insight
- Humoral and cellular responses to spike of δ SARS-CoV-2 variant in vaccinated patients with immune-mediated inflammatory diseases
- (2022) Linda Petrone et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod
- (2022) Lil Meyer-Arndt et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Characterization of immune profile in an aging multiple sclerosis clinic population
- (2022) Andrew P. Keegan et al. Multiple Sclerosis and Related Disorders
- Innate Lymphoid Cells - Neglected Players in Multiple Sclerosis
- (2022) Negar Sadeghi Hassanabadi et al. Frontiers in Immunology
- Cellular and Humoral Immune Response to a Third Dose of BNT162b2 COVID-19 Vaccine – A Prospective Observational Study
- (2022) Jonas Herzberg et al. Frontiers in Immunology
- Immune aging in multiple sclerosis is characterized by abnormal CD4 T cell activation and increased frequencies of cytotoxic CD4 T cells with advancing age
- (2022) Leah Zuroff et al. EBioMedicine
- Booster dose of SARS-CoV-2 mRNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: A prospective multicenter longitudinal study
- (2022) Chiara Farroni et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Spike is the most recognized antigen in the whole-blood platform in both acute and convalescent COVID-19 patients
- (2021) Alessandra Aiello et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy
- (2021) Sokratis A. Apostolidis et al. NATURE MEDICINE
- Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA Vaccine
- (2021) Chiara Agrati et al. Microorganisms
- Humoral- and T-Cell–Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies
- (2021) Carla Tortorella et al. NEUROLOGY
- Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis
- (2021) Steve Simpson-Yap et al. NEUROLOGY
- mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern
- (2021) Rishi R. Goel et al. SCIENCE
- COVID-19 outcomes in persons with multiple sclerosis treated with rituximab
- (2021) Rajesh B Iyer et al. Multiple Sclerosis and Related Disorders
- T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study
- (2021) Adrienn Angyal et al. Lancet Microbe
- Memory CD4+ T Cells in Immunity and Autoimmune Diseases
- (2020) Itay Raphael et al. Cells
- Treatment of Multiple Sclerosis: A Review
- (2020) Stephen L. Hauser et al. AMERICAN JOURNAL OF MEDICINE
- Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod
- (2020) Christian Foerch et al. Multiple Sclerosis and Related Disorders
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
- (2018) Alan J Thompson et al. LANCET NEUROLOGY
- Characterization of naïve, memory and effector T cells in progressive multiple sclerosis
- (2017) Birgitte Romme Nielsen et al. JOURNAL OF NEUROIMMUNOLOGY
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2017) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- The inverted CD4:CD8 ratio is associated with gender-related changes in oxidative stress during aging
- (2015) Guilherme Cerutti Muller et al. CELLULAR IMMUNOLOGY
- The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis
- (2015) Samuel F. Hunter et al. CNS DRUGS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search